Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 4/2016

01-08-2016 | Original Article

Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study

Authors: Hsin-Hsu Chou, Mei-Ju Chen, Yuan-Yow Chiou

Published in: Clinical and Experimental Nephrology | Issue 4/2016

Login to get access

Abstract

Background

The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN).

Methods

This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined.

Results

There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications.

Conclusion

A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
Literature
1.
2.
3.
Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34:866–72.CrossRefPubMed
4.
5.
Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924–9.PubMed
6.
7.
Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs. 2006;66:1191–207.CrossRefPubMed
8.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.CrossRefPubMed
9.
Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf. 2007;6:445–9.CrossRefPubMed
10.
Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19:703–10.CrossRefPubMed
11.
Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000;58:51–61.CrossRefPubMed
12.
Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. New Engl J Med. 2000;343:1156–62.CrossRefPubMed
13.
Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.CrossRefPubMed
14.
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med. 2005;353:2219–28.CrossRefPubMed
15.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.CrossRefPubMedPubMedCentral
16.
Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38:69–78.CrossRefPubMed
17.
Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968–75.CrossRefPubMed
18.
Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol. 2001;28:2103–8.PubMed
19.
Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus. 2009;18:139–43.CrossRefPubMed
20.
Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child. 2010;95:1059–61.CrossRefPubMed
21.
Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005;19:199–206.CrossRefPubMed
22.
Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–6.CrossRefPubMed
23.
Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc. 2004;36:517S–20S.CrossRefPubMed
24.
Burg M, Saemann MD, Wieser C, Kramer S, Fischer W, Lhotta K. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. Transplant Proc. 2009;41:4159–64.CrossRefPubMed
25.
Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc. 2006;38:2396–7.CrossRefPubMed
26.
Meneses Rde P, Kotsifas CH. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transplant. 2009;13:188–93.CrossRefPubMed
27.
Traitanon O, Avihingsanon Y, Kittikovit V, Townamchai N, Kanjanabuch T, Praditpornsilpa K, et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008;17:744–51.CrossRefPubMed
28.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMed
29.
Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–57.CrossRefPubMed
30.
Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29:771–5.CrossRefPubMed
31.
Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–63.PubMed
32.
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. New Engl J Med. 2006;354:2473–83.CrossRefPubMed
33.
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.CrossRefPubMed
34.
Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248–54.CrossRefPubMed
35.
Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62:873–80.CrossRefPubMed
36.
Kitiyakara C, Ophascharoensuk V, Changsirikulchai S, Ingsathit A, Tankee P, Sangpanich A, et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol. 2008;69:90–101.CrossRefPubMed
37.
Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484–93.CrossRefPubMed
38.
Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68:2095–104.CrossRefPubMed
39.
Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61:74–87.CrossRefPubMed
40.
41.
Hogan J, Schwenk MH, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int. 2012;82:1256–60.CrossRefPubMed
42.
Paredes A. Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol. 2007;22:1077–82.CrossRefPubMed
43.
Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.CrossRefPubMedPubMedCentral
44.
Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, et al. Lupus nephritis: induction therapy in severe lupus nephritis—should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013;8:147–53.CrossRefPubMed
45.
Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford). 2009;48:944–52.CrossRef
46.
Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22:1933–42.CrossRefPubMed
47.
Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:375–83.CrossRefPubMedPubMedCentral
Metadata
Title
Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study
Authors
Hsin-Hsu Chou
Mei-Ju Chen
Yuan-Yow Chiou
Publication date
01-08-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1171-6

Other articles of this Issue 4/2016

Clinical and Experimental Nephrology 4/2016 Go to the issue

Guideline

Clinical guides for atypical hemolytic uremic syndrome in Japan

Original Article

Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study

Original Article

Extracapillary proliferation and arteriolar hyalinosis are associated with long-term kidney survival in IgA nephropathy

Original Article

Clinical manifestations of Henoch–Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR)

Original Article

Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: results of a multicenter cohort study

Images in Nephrology

Toxic epidermal necrolysis due to cyclophosphamide

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits